CXCR4 and neoplasm: I.p. delivered OVV-CXCR4-A controlled tumor growth for 4–5 weeks, and then the tumor progressed, extending survival by over 14 days compared with mice treated with sCXCR4-A (p < 0.001; Figure 1B) or by ∼10 days compared with the OVV-treated counterparts.